A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Clinical trial NCT07221253 · RECRUITING

Trial details

NCT number: NCT07221253
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Biliary Tract Cancer

Start date: 2025-12-04
Primary completion: 2029-07-31
Enrollment: 1100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.